Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, netarsudil mesylate (Rhokiinsa®) cannot be endorsed for use within NHS Wales for the reduction of elevated intraocular pressure in adult patients with primary open-angle glaucoma or ocular hypertension. This product is currently not marketed in the UK. |
||
|
||
Medicine details |
||
| Medicine name | netarsudil mesylate (Rhokiinsa®) | |
| Formulation | 200 microgram/ml eye drop solution | |
| Reference number | 3751 | |
| Indication | For the reduction of elevated intraocular pressure in adult patients with primary open-angle glaucoma or ocular hypertension |
|
| Company | Aerie Pharmaceuticals | |
| BNF chapter | Eye | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 16/06/2020 | |
| Further information This product is currently not marketed in the UK. |
||